Difficulty: Medium
Average Score: 93%
Practice
In addition to a risk of major congenital malformations, which antiepileptic drug is also associated with an elevated risk of autism spectrum disorders and lower IQ at age 6?
Correct answer
C
Rationale
The correct answer is C) valproate. Valproate is known to pose a significant risk of major congenital malformations when used during pregnancy. Additionally, research has shown that exposure to valproate in utero is associated with an increased risk of autism spectrum disorders and lower IQ in children at age 6. This makes valproate a high-risk choice for women of childbearing potential or pregnant women.
Option A) carbamazepine and Option D) phenytoin are both antiepileptic drugs, but they are not specifically linked to an elevated risk of autism spectrum disorders or lower IQ in children. Lamotrigine, Option B, is a safer alternative for women who are pregnant or planning to conceive as it has a lower risk of major congenital malformations compared to valproate.
Educationally, understanding the teratogenic risks associated with psychotropic medications is crucial for healthcare professionals, especially those working with women of childbearing potential. It underscores the importance of conducting a thorough risk-benefit analysis when prescribing medications to this population to mitigate potential harm to both the mother and the developing fetus. This knowledge empowers healthcare providers to make informed decisions that prioritize the well-being of their patients.
Option A) carbamazepine and Option D) phenytoin are both antiepileptic drugs, but they are not specifically linked to an elevated risk of autism spectrum disorders or lower IQ in children. Lamotrigine, Option B, is a safer alternative for women who are pregnant or planning to conceive as it has a lower risk of major congenital malformations compared to valproate.
Educationally, understanding the teratogenic risks associated with psychotropic medications is crucial for healthcare professionals, especially those working with women of childbearing potential. It underscores the importance of conducting a thorough risk-benefit analysis when prescribing medications to this population to mitigate potential harm to both the mother and the developing fetus. This knowledge empowers healthcare providers to make informed decisions that prioritize the well-being of their patients.